FR16C0021I1 - - Google Patents
Info
- Publication number
- FR16C0021I1 FR16C0021I1 FR16C0021C FR16C0021I1 FR 16C0021 I1 FR16C0021 I1 FR 16C0021I1 FR 16C0021 C FR16C0021 C FR 16C0021C FR 16C0021 I1 FR16C0021 I1 FR 16C0021I1
- Authority
- FR
- France
- Prior art keywords
- compounds
- cancer
- treatment
- disclosed
- solvates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72457805P | 2005-10-07 | 2005-10-07 | |
US80284006P | 2006-05-23 | 2006-05-23 | |
PCT/US2006/039126 WO2007044515A1 (fr) | 2005-10-07 | 2006-10-05 | Inhibiteurs de mek et procedes pour les utiliser |
Publications (2)
Publication Number | Publication Date |
---|---|
FR16C0021I1 true FR16C0021I1 (fr) | 2016-06-24 |
FR16C0021I2 FR16C0021I2 (fr) | 2017-04-14 |
Family
ID=37728416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR16C0021C Active FR16C0021I2 (fr) | 2005-10-07 | 2016-05-19 | Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives |
Country Status (32)
Country | Link |
---|---|
US (8) | US7803839B2 (fr) |
EP (1) | EP1934174B1 (fr) |
JP (8) | JP5129143B2 (fr) |
KR (2) | KR20130058072A (fr) |
CN (5) | CN104892582B (fr) |
AT (1) | ATE504565T1 (fr) |
AU (1) | AU2006302415B2 (fr) |
BR (1) | BRPI0617165B1 (fr) |
CA (3) | CA2622755C (fr) |
CY (2) | CY1111670T1 (fr) |
DE (1) | DE602006021205D1 (fr) |
DK (1) | DK1934174T3 (fr) |
EA (3) | EA025871B9 (fr) |
ES (1) | ES2365070T3 (fr) |
FR (1) | FR16C0021I2 (fr) |
GE (1) | GEP20125456B (fr) |
HK (2) | HK1119698A1 (fr) |
HR (1) | HRP20110498T1 (fr) |
HU (1) | HUS1600021I1 (fr) |
IL (5) | IL189900A (fr) |
LT (1) | LTC1934174I2 (fr) |
LU (1) | LU93078I2 (fr) |
MY (1) | MY162174A (fr) |
NL (1) | NL300809I2 (fr) |
NO (4) | NO347091B1 (fr) |
NZ (1) | NZ567140A (fr) |
PL (1) | PL1934174T3 (fr) |
PT (1) | PT1934174E (fr) |
RS (1) | RS51782B (fr) |
SI (1) | SI1934174T1 (fr) |
WO (1) | WO2007044515A1 (fr) |
ZA (1) | ZA200802075B (fr) |
Families Citing this family (245)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1802579T3 (da) * | 2004-10-20 | 2014-01-20 | Merck Serono Sa | Derivater af 3-arylaminopyridin |
EA025871B9 (ru) * | 2005-10-07 | 2017-08-31 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
EP2056829B9 (fr) * | 2006-08-16 | 2012-09-26 | Exelixis, Inc. | Procédés d'utilisation de modulateurs pi3k et mek |
EP2113500A1 (fr) | 2006-10-31 | 2009-11-04 | Takeda Pharmaceutical Company Limited | Inhibitêur du kinàse MAPK/ERK |
WO2008076415A1 (fr) * | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Procédés d'utilisation d'inhibiteurs de mek |
WO2008124085A2 (fr) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2 |
CN101679235A (zh) * | 2007-05-10 | 2010-03-24 | 辉瑞有限公司 | 氮杂环丁烷衍生物和它们作为前列腺素e2拮抗剂的用途 |
WO2009012256A1 (fr) | 2007-07-16 | 2009-01-22 | Genentech, Inc. | Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation |
ES2381788T3 (es) | 2007-07-16 | 2012-05-31 | Genentech, Inc. | Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso |
GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
WO2009093008A1 (fr) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Dérivés de thiénopyridine utilisés comme inhibiteurs de mek |
IL287292B (en) | 2008-01-31 | 2022-09-01 | Genentech Inc | and fusion antibody-drug-cd79b engineered antibodies cysteine- |
UA127472C2 (uk) | 2008-03-18 | 2023-09-06 | Дженентек, Інк. | Комбінація кон'югата анти-her2-антитіло-лікарський засіб і хіміотерапевтичного засобу і спосіб застосування |
GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
US8492427B2 (en) | 2008-07-01 | 2013-07-23 | Genentech, Inc. | Isoindolones derivatives as MEK kinase inhibitors and methods of use |
PE20110570A1 (es) * | 2008-07-01 | 2011-08-26 | Genentech Inc | Heterociclos biciclicos sustituidos |
US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
BRPI1006189A2 (pt) | 2009-03-12 | 2020-08-18 | Genentech Inc | uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer |
JP5781066B2 (ja) | 2009-05-27 | 2015-09-16 | ジェネンテック, インコーポレイテッド | p110δに対して選択的な二環式ピリミジンPI3K阻害剤化合物及び使用方法 |
US8263633B2 (en) | 2009-09-28 | 2012-09-11 | F. Hoffman-La Roche Ag | Benzoxepin PI3K inhibitor compounds and methods of use |
ES2444779T3 (es) | 2009-09-28 | 2014-02-26 | F. Hoffmann-La Roche Ag | Compuestos de benzoxazepina inhibidores de la PI3K y su utilización en el tratamiento de cáncer |
EP2488178B1 (fr) * | 2009-10-12 | 2016-11-16 | F.Hoffmann-La Roche Ag | Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek |
EA201200651A1 (ru) | 2009-11-04 | 2012-12-28 | Новартис Аг | Гетероциклические сульфонамидные производные, применимые в качестве ингибиторов мек |
US20110165155A1 (en) | 2009-12-04 | 2011-07-07 | Genentech, Inc. | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 |
EP2526102B1 (fr) | 2010-01-22 | 2017-03-08 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Inhibiteurs de la PI3 kinase |
BR112012019635A2 (pt) | 2010-02-22 | 2016-05-03 | Hoffmann La Roche | compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso |
EP3028699B1 (fr) | 2010-02-25 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Mutations braf conférant une résistance aux inhibiteurs de braf |
ES2714875T3 (es) | 2010-03-09 | 2019-05-30 | Dana Farber Cancer Inst Inc | Métodos de diagnóstico y tratamiento del cáncer en pacientes que presentan o desarrollan resistencia a una primera terapia del cáncer |
WO2011121317A1 (fr) | 2010-04-01 | 2011-10-06 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazo[1,2-b][1,2,3]thiadiazoles en tant qu'inhibiteurs de la kinase protéique ou de la kinase lipidique |
ES2601004T3 (es) | 2010-04-07 | 2017-02-13 | F. Hoffmann-La Roche Ag | Compuestos pirazol-4-il-heterociclil-carboxamida y métodos de uso |
BR112012026213B1 (pt) | 2010-04-15 | 2021-12-28 | Medimmune Limited | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa |
BR112012028530A2 (pt) | 2010-05-07 | 2017-12-19 | Genentech Inc | composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno |
EP2593455B1 (fr) | 2010-07-14 | 2015-03-18 | F.Hoffmann-La Roche Ag | COMPOSÉS INHIBITEURS DE LA PI3K DE TYPE PURINE ET PROCÉDÉS & xA; D'UTILISATION |
EP2598661B1 (fr) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Compositions de stabilisation d'adn, d'arn, de protéines salivaires et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes |
EP2598660B1 (fr) | 2010-07-26 | 2017-03-15 | Biomatrica, INC. | Compositions de stabilisation d'adn, d'arn, de protéines dans le sang et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes |
KR20180031823A (ko) | 2010-09-01 | 2018-03-28 | 질레드 코네티컷 인코포레이티드 | 피리다지논, 그의 제조 방법 및 사용 방법 |
WO2012031004A1 (fr) | 2010-09-01 | 2012-03-08 | Gilead Connecticut, Inc. | Pyridinones/pyrazinones, leur procédé de fabrication et leur méthode d'utilisation |
WO2012052745A1 (fr) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinaisons d'inhibiteurs de pi3k avec un second agent antitumoral |
EP2640366A2 (fr) | 2010-11-15 | 2013-09-25 | Exelixis, Inc. | Benzoxazépines en tant qu'inhibiteurs de pi3k/mtor et leurs méthodes d'utilisation et de fabrication |
TWI441824B (zh) | 2010-12-16 | 2014-06-21 | Hoffmann La Roche | 三環pi3k抑制劑化合物及其使用方法 |
CA2825028A1 (fr) | 2011-02-09 | 2012-08-16 | F. Hoffman-La Roche Ag | Composes heterocycliques en tant qu'inhibiteurs de pi3 kinase |
EP2688891B1 (fr) | 2011-03-21 | 2017-11-15 | F. Hoffmann-La Roche AG | Composés de benzoxazépine sélectifs pour pi3k p110 delta et leurs méthodes d'utilisation |
CN102718750B (zh) * | 2011-03-31 | 2015-03-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含吖啶环的氨基吡啶类衍生物及其用途 |
KR20140022053A (ko) | 2011-04-01 | 2014-02-21 | 제넨테크, 인크. | Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법 |
CN103857395A (zh) | 2011-04-01 | 2014-06-11 | 基因泰克公司 | Akt抑制剂化合物和阿比特龙的组合及使用方法 |
MX349366B (es) | 2011-05-19 | 2017-07-26 | Centro Nac De Investigaciones Oncologicas (Cnio) | Compuestos novedosos. |
EP2524918A1 (fr) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines en tant qu'inhibiteurs de kinase |
WO2012164060A1 (fr) | 2011-06-03 | 2012-12-06 | F. Hoffmann-La Roche Ag | Méthodes de traitement du mésothéliome au moyen d'un composé inhibiteur de pi3k |
TW201840336A (zh) | 2011-08-01 | 2018-11-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
US9260425B2 (en) | 2011-08-12 | 2016-02-16 | Genetech, Inc. | Pyrazolo[3,4-c]pyridine compounds and methods of use |
TWI570117B (zh) | 2011-09-27 | 2017-02-11 | 赫孚孟拉羅股份公司 | 吡唑-4-基-雜環甲醯胺化合物及使用方法 |
KR101877598B1 (ko) | 2011-10-14 | 2018-07-11 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
MX2014004991A (es) * | 2011-10-28 | 2014-05-22 | Genentech Inc | Combinaciones terapeuticas y metodos para tratar el melanoma. |
UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
ES2552514T3 (es) | 2011-11-03 | 2015-11-30 | Hoffmann-La Roche Ag | Compuestos bicíclicos de piperazina |
CA2853967A1 (fr) | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | Composes 8-fluorophtalazin-1(2h)-one comme inhibiteurs de l'activite btk |
MX2014005289A (es) | 2011-11-03 | 2014-05-30 | Hoffmann La Roche | Compuestos de piperazina alquilados. |
EP2592103A1 (fr) | 2011-11-08 | 2013-05-15 | Adriacell S.p.A. | Dérivés d'aldéhyde de polymère |
RU2014124530A (ru) | 2011-11-23 | 2015-12-27 | Идженика, Инк. | Антитела к cd98 и способы их применения |
WO2013082511A1 (fr) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Procédés pour surmonter la résistance tumorale aux antagonistes de vegf |
CN103204822B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途 |
WO2013113102A1 (fr) | 2012-02-01 | 2013-08-08 | The Governors Of The University Of Alberta | Utilisation de pdgfr-a comme marqueur de diagnostic pour le cancer papillaire de la thyroïde |
WO2013169858A1 (fr) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Méthodes de diagnostic et de traitement chez des patients ayant ou présentant un risque de développer une résistance à une thérapie anticancéreuse |
NZ702244A (en) | 2012-06-08 | 2017-06-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
EP2867232B1 (fr) | 2012-06-27 | 2018-08-08 | F.Hoffmann-La Roche Ag | Composés de 5-azaindazole et procédés d'utilisation |
CN104797270A (zh) | 2012-08-02 | 2015-07-22 | 基因泰克公司 | 抗etbr抗体和免疫偶联物 |
CA2879665A1 (fr) | 2012-08-02 | 2014-02-06 | Genentech, Inc. | Anticorps et immunoconjugues anti-etbr |
WO2014028461A2 (fr) * | 2012-08-13 | 2014-02-20 | The Rockefeller University | Traitement et diagnostic du mélanome |
BR112015003418A2 (pt) | 2012-08-17 | 2017-07-04 | Hoffmann La Roche | produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica. |
RU2612251C2 (ru) | 2012-08-30 | 2017-03-03 | Ф. Хоффманн-Ля Рош Аг | Соединения диоксин- и оксазин[2,3-d]пиримидина в качестве ингибиторов фосфоинозитид-3-киназы и способы их применения |
DK2900657T3 (da) | 2012-09-26 | 2020-05-04 | Hoffmann La Roche | Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse |
US20150231240A1 (en) | 2012-10-09 | 2015-08-20 | Igenica Biotherapeutics, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
ES2660029T3 (es) | 2012-10-12 | 2018-03-20 | Medimmune Limited | Conjugados de anticuerpo-pirrolobenzodiazepinas |
HUE035694T2 (en) | 2012-10-12 | 2018-05-28 | Adc Therapeutics Sa | Pirrolobenzodiazepine anti-CD22 antibody conjugates |
SI2906296T1 (en) | 2012-10-12 | 2018-06-29 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
ES2703151T3 (es) | 2012-10-12 | 2019-03-07 | Adc Therapeutics Sa | Conjugados de anticuerpos de pirrolobenzodiazepinas |
EP2906250B1 (fr) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Conjugués pyrrolobenzodiazepine-anticorps anti-psma |
NZ707486A (en) | 2012-10-12 | 2018-09-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
TR201902494T4 (tr) | 2012-10-12 | 2019-03-21 | Medimmune Ltd | Pirrolobenzodiazepinler ve onların konjugatları. |
PT2839860T (pt) | 2012-10-12 | 2019-07-29 | Medimmune Ltd | Pirrolobenzodiazepinas e conjugados das mesmas |
CR20200237A (es) * | 2012-10-12 | 2020-07-26 | Exelixis Inc | Proceso novedoso para la elaboración de compuestos para su uso en el tratamiento del cáncer (diviisional 2015-0245) |
WO2014074785A1 (fr) | 2012-11-08 | 2014-05-15 | Ludwig Institute For Cancer Research Ltd. | Procédés de prédiction de l'issue et du traitement du cancer du sein |
CA2889381C (fr) * | 2012-11-15 | 2023-01-03 | Duquesne University Of The Holy Ghost | Inhibiteurs de mek sous forme de promedicaments a base d'ester d'acide carboxylique |
TW201441193A (zh) * | 2012-12-06 | 2014-11-01 | Kyowa Hakko Kirin Co Ltd | 吡啶酮化合物 |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
CN105246894A (zh) | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
EA031585B1 (ru) | 2012-12-21 | 2019-01-31 | Медимьюн Лимитед | Пирролобензодиазепины и их конъюгаты |
KR20150118159A (ko) | 2013-02-22 | 2015-10-21 | 에프. 호프만-라 로슈 아게 | 암의 치료 방법 및 약물 내성의 예방 방법 |
US9968687B2 (en) | 2013-02-22 | 2018-05-15 | Abbvie Stemcentrx Llc | Anti-DLL3 antibody drug conjugates |
WO2014133071A1 (fr) | 2013-02-27 | 2014-09-04 | 第一三共株式会社 | Procédé de prédiction de la réactivité à un composé inhibant la voie de transduction du signal de mapk |
JP6444902B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びその結合体 |
NZ710745A (en) | 2013-03-13 | 2019-03-29 | Genentech Inc | Pyrrolobenzodiazepines and conjugates thereof |
CN105142674B (zh) | 2013-03-13 | 2018-11-13 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓和其结合物 |
CN105246508A (zh) | 2013-03-14 | 2016-01-13 | 基因泰克公司 | Mek抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法 |
EA030611B1 (ru) | 2013-03-15 | 2018-08-31 | Кэнсер Рисерч Текнолоджи, Ллк | Способы и композиции для модуляции гамма-глутамилового цикла |
WO2014153495A2 (fr) | 2013-03-22 | 2014-09-25 | University Of Hawaii | Nouveaux inhibiteurs de stats3 |
AU2014274660B2 (en) | 2013-06-06 | 2019-05-16 | Pierre Fabre Médicament | Anti-C10orf54 antibodies and uses thereof |
WO2015002729A2 (fr) | 2013-06-13 | 2015-01-08 | Biomatrica, Inc. | Stabilisation de cellules |
CN105358545A (zh) | 2013-07-03 | 2016-02-24 | 豪夫迈·罗氏有限公司 | 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物 |
KR20160044042A (ko) | 2013-08-28 | 2016-04-22 | 스템센트알엑스 인코포레이티드 | 부위-특이적 항체 접합 방법 및 조성물 |
US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
EP3054985B1 (fr) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Conjugués anticorps-pyrrolobenzodiazépine |
WO2015052535A1 (fr) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Conjugués anticorps-pyrrolobenzodiazépine |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
EP3054983B1 (fr) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Conjugués anticorps-pyrrolobenzodiazépines |
RU2646758C2 (ru) | 2013-12-05 | 2018-03-07 | Ф. Хоффманн-Ля Рош Аг | Гетероарил пиридоны и азапиридоны с электрофильной функциональностью |
WO2015108203A1 (fr) | 2014-01-15 | 2015-07-23 | 株式会社オーダーメードメディカルリサーチ | Composition pharmaceutique thérapeutique utilisant un anticorps anti-slc6a6 |
CN104788365B (zh) * | 2014-01-16 | 2018-08-10 | 上海艾力斯医药科技有限公司 | 异烟酰胺衍生物、其制备方法及应用 |
JP6554480B2 (ja) | 2014-03-18 | 2019-07-31 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | オキセパン−2−イル−ピラゾール−4−イル−ヘテロシクリル−カルボキサミド化合物と使用方法 |
GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
CA2946112C (fr) | 2014-04-18 | 2020-11-24 | The Governors Of The University Of Alberta | Therapie ciblee pour restaurer le transport de l'iode radioactif pour traiter le cancer de la thyroide |
SG10201809411PA (en) | 2014-04-25 | 2018-11-29 | Genentech Inc | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
WO2015172073A1 (fr) | 2014-05-08 | 2015-11-12 | Cornell University | Gels bioadhésifs et procédés d'utilisation |
WO2015182734A1 (fr) * | 2014-05-30 | 2015-12-03 | 協和発酵キリン株式会社 | Composé hétérocyclique contenant de l'azote |
WO2015191632A1 (fr) | 2014-06-10 | 2015-12-17 | Biomatrica, Inc. | Stabilisation de thrombocytes à des températures ambiantes |
CN106573060A (zh) | 2014-07-15 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物 |
US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
SG10201809668TA (en) | 2014-09-12 | 2018-11-29 | Genentech Inc | Anti-her2 antibodies and immunoconjugates |
US10077318B2 (en) | 2014-09-12 | 2018-09-18 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
MA40575A (fr) | 2014-09-17 | 2016-03-24 | Genentech Inc | Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés |
CN107124870A (zh) | 2014-09-17 | 2017-09-01 | 基因泰克公司 | 包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物 |
CN106922146B (zh) | 2014-10-02 | 2020-05-26 | 豪夫迈·罗氏有限公司 | 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物 |
TW201625243A (zh) | 2014-10-14 | 2016-07-16 | 艾克塞里克斯公司 | 用於治療黑素瘤之藥物組合 |
AU2015352545B2 (en) | 2014-11-25 | 2020-10-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
CN114230664A (zh) | 2014-12-11 | 2022-03-25 | 皮埃尔法布雷医药公司 | 抗c10orf54抗体及其用途 |
WO2016095088A1 (fr) * | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Inhibiteurs d'erk |
WO2016095089A1 (fr) * | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Inhibiteurs d'erk |
SG10202100799PA (en) | 2014-12-18 | 2021-03-30 | Hoffmann La Roche | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
CN107614015A (zh) | 2015-05-30 | 2018-01-19 | 豪夫迈·罗氏有限公司 | 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法 |
EP3307780A1 (fr) | 2015-06-15 | 2018-04-18 | Genentech, Inc. | Anticorps et immunoconjugués |
AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
EP4272735A1 (fr) | 2015-06-30 | 2023-11-08 | Genentech, Inc. | Comprimés à libération immédiate contenant un médicament et procédés de formation des comprimés |
TW202108592A (zh) | 2015-07-02 | 2021-03-01 | 瑞士商赫孚孟拉羅股份公司 | 苯并氧氮呯噁唑啶酮化合物及其用途 |
CN107995911B (zh) | 2015-07-02 | 2020-08-04 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 |
WO2017033113A1 (fr) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Associations thérapeutiques d'un inhibiteur de mek et d'un inhibiteur de btk |
JP2018532990A (ja) | 2015-09-04 | 2018-11-08 | オービーアイ ファーマ,インコーポレイテッド | グリカンアレイおよび使用の方法 |
CN108601839B (zh) | 2015-11-03 | 2021-10-26 | 基因泰克公司 | 用于治疗癌症的Bcl-2抑制剂和MEK抑制剂组合产品 |
WO2017087280A1 (fr) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Procédés de traitement d'un cancer positif her2 |
KR20180081591A (ko) | 2015-11-19 | 2018-07-16 | 제넨테크, 인크. | B-raf 억제제 및 면역 체크포인트 억제제를 사용하여 암을 치료하는 방법 |
CN113588501A (zh) | 2015-12-08 | 2021-11-02 | 生物马特里卡公司 | 降低红细胞沉降速率 |
CN105330643B (zh) * | 2015-12-09 | 2017-12-05 | 苏州明锐医药科技有限公司 | 卡比替尼的制备方法 |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
JP6577143B2 (ja) | 2016-02-29 | 2019-09-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ブルトンチロシンキナーゼの阻害剤を含む剤形組成物 |
JP7085985B2 (ja) | 2016-03-04 | 2022-06-17 | 大鵬薬品工業株式会社 | 悪性腫瘍治療用製剤及び組成物 |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
CN109311995A (zh) | 2016-03-29 | 2019-02-05 | 台湾浩鼎生技股份有限公司 | 抗体、药物组合物和方法 |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
AU2017249229A1 (en) | 2016-04-15 | 2018-10-04 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
BR112018071683A2 (pt) | 2016-04-22 | 2019-02-19 | Obi Pharma, Inc. | método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CN106045969B (zh) * | 2016-05-27 | 2019-04-12 | 湖南欧亚药业有限公司 | 一种卡比替尼的合成方法 |
CN109311876B (zh) | 2016-06-16 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 杂芳基雌激素受体调节剂及其用途 |
US20170362228A1 (en) | 2016-06-16 | 2017-12-21 | Genentech, Inc. | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
CN106220607B (zh) * | 2016-07-27 | 2018-09-18 | 成都百事兴科技实业有限公司 | 一种s-3-(哌啶-2-基)-氮杂环丁烷-3-醇的合成方法 |
AU2017302038B2 (en) | 2016-07-27 | 2024-03-21 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
WO2018023121A1 (fr) | 2016-07-29 | 2018-02-01 | Obi Pharma, Inc. | Anticorps humains, compositions pharmaceutiques et procédés |
CN109689102A (zh) | 2016-08-12 | 2019-04-26 | 基因泰克公司 | Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法 |
JP2019534251A (ja) | 2016-09-29 | 2019-11-28 | ジェネンテック, インコーポレイテッド | Mek阻害剤、pd−1軸阻害剤、及びタキサンを用いた併用療法 |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
CA3044274A1 (fr) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Molecules biologiques conjuguees, compositions pharmaceutiques et procedes |
UA123889C2 (uk) | 2017-02-08 | 2021-06-16 | Ейдісі Терапьютікс Са | Кон'югати піролобензодіазепін-антитіло |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
RS61795B1 (sr) | 2017-02-08 | 2021-06-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin antitela |
CN106866624B (zh) * | 2017-02-27 | 2017-12-26 | 济宁医学院 | 一种卡比替尼的化学合成方法 |
EP3606536A4 (fr) | 2017-04-04 | 2020-12-16 | University of Miami | Biomarqueurs indicatifs du cancer de la prostate et traitement associé |
WO2018192944A1 (fr) | 2017-04-18 | 2018-10-25 | Medimmune Limited | Conjugués de pyrrolobenzodiazépine |
BR112019021680A2 (pt) | 2017-04-20 | 2020-05-12 | Adc Therapeutics Sa | Terapia de combinação com conjugado anticorpo-fármaco anti-cd25?? |
EP3612234B1 (fr) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Polythérapie avec un conjugué anticorps anti-axl-médicament |
WO2018229218A1 (fr) | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Régimes posologiques pour l'administration d'un cam anti-cd25 |
MX2019015042A (es) | 2017-06-14 | 2020-08-06 | Adc Therapeutics Sa | Regimen de dosificacion. |
AU2018316532B2 (en) | 2017-08-18 | 2022-11-24 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
AU2018329925A1 (en) | 2017-09-08 | 2020-03-05 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for cancer |
EP3752200A1 (fr) | 2018-02-13 | 2020-12-23 | Vib Vzw | Ciblage d'une maladie résiduelle minimale dans le cancer avec des antagonistes de rxr |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
CN111867594A (zh) | 2018-03-19 | 2020-10-30 | 大鹏药品工业株式会社 | 包含烷基硫酸钠的药物组合物 |
TW202003020A (zh) | 2018-03-21 | 2020-01-16 | 美國科羅拉多州立大學研究基金會 | 癌症疫苗組合物及其使用方法 |
CN111902773A (zh) | 2018-03-26 | 2020-11-06 | 富士胶片株式会社 | 感光性树脂组合物及其制造方法、抗蚀剂膜、图案形成方法以及电子器件的制造方法 |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
US20220111065A1 (en) | 2018-05-23 | 2022-04-14 | Adc Therapeutics Sa | Molecular adjuvant |
US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
GB201811364D0 (en) | 2018-07-11 | 2018-08-29 | Adc Therapeutics Sa | Combination therapy |
BR112021000934A2 (pt) | 2018-07-20 | 2021-04-27 | Pierre Fabre Medicament | receptor para vista |
MX2021001908A (es) | 2018-08-31 | 2021-08-19 | Adc Therapeutics Sa | Terapia de combinacion. |
CN112867803A (zh) | 2018-10-16 | 2021-05-28 | 诺华股份有限公司 | 单独的或与免疫标志物组合的肿瘤突变负荷作为生物标志物用于预测对靶向疗法的应答 |
WO2020106306A1 (fr) * | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
JP2022510586A (ja) * | 2018-11-20 | 2022-01-27 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置のためのチエニル-アニリン化合物 |
WO2020106303A1 (fr) * | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau |
WO2020109251A1 (fr) | 2018-11-29 | 2020-06-04 | Adc Therapeutics Sa | Régime posologique |
GB201820725D0 (en) | 2018-12-19 | 2019-01-30 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine resistance |
US20220347309A1 (en) | 2018-12-19 | 2022-11-03 | Adc Therapeutics Sa | Pyrrolobenzodiazepine resistance |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
WO2020187674A1 (fr) | 2019-03-15 | 2020-09-24 | Sandoz Ag | Hémisuccinate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl) azétidin-1-yl]méthanone cristallin |
EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
PT3946464T (pt) | 2019-03-29 | 2022-11-16 | Medimmune Ltd | Compostos e seus conjugados |
TWI735210B (zh) | 2019-04-26 | 2021-08-01 | 中國醫藥大學 | Adam9抑制劑作為免疫調節劑之用途 |
GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
CN114302746A (zh) | 2019-06-10 | 2022-04-08 | Adc治疗有限公司 | 包含抗cd25抗体药物缀合物和另一剂的组合疗法 |
WO2020249528A1 (fr) | 2019-06-10 | 2020-12-17 | Adc Therapeutics Sa | Polythérapie comprenant un conjugué médicament-anticorps anti-cd19 et un inhibiteur de pi3k ou un agent secondaire |
BR112022001125A2 (pt) | 2019-07-22 | 2022-03-15 | Lupin Ltd | Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos |
GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
US20240123081A1 (en) | 2019-10-25 | 2024-04-18 | Medimmune, Llc | Branched moiety for use in conjugates |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
JP2023509845A (ja) | 2019-12-13 | 2023-03-10 | インスピルナ,インコーポレーテッド | 金属塩及びその使用 |
CN111170990B (zh) * | 2020-01-16 | 2021-01-05 | 广州科锐特生物科技有限公司 | 一种3-哌啶-2-基-氮杂环丁烷-3-醇衍生物的制备方法 |
TW202140076A (zh) | 2020-01-22 | 2021-11-01 | 英商梅迪繆思有限公司 | 化合物及其軛合物 |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
MX2022009052A (es) | 2020-01-22 | 2022-08-15 | Medimmune Ltd | Compuestos y conjugados de estos. |
GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
TW202200146A (zh) | 2020-04-10 | 2022-01-01 | 日商大鵬藥品工業股份有限公司 | 使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法 |
EP4135775A1 (fr) | 2020-04-16 | 2023-02-22 | Regeneron Pharmaceuticals, Inc. | Procédés de conjugaison de diels-alder |
GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
EP3915576A1 (fr) | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Récepteurs d'antigène chimérique spécifiques pour p95her2 et leurs utilisations |
EP3939999A1 (fr) | 2020-07-14 | 2022-01-19 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Anticorps neutralisant la sous-unité alpha du récepteur de l'interleukine 11 (il11ra) et leurs utilisations |
GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
GB202012161D0 (en) | 2020-08-05 | 2020-09-16 | Adc Therapeutics Sa | Combination therapy |
AU2021326530A1 (en) | 2020-08-14 | 2023-04-20 | Guangzhou Lupeng Pharmaceutical Company Ltd. | Dosage form compositions comprising an inhibitor of btk and mutants thereof |
GB202015226D0 (en) | 2020-09-25 | 2020-11-11 | Adc Therapeutics S A | Pyrrol obenzodiazepine-antibody conugates and uses thereof |
GB202015916D0 (en) | 2020-10-07 | 2020-11-18 | Adc Therapeutics Sa | Combination therapy |
US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
US20240173329A1 (en) | 2021-03-09 | 2024-05-30 | Genentech, Inc. | Belvarafenib for use in treatment of brain cancers |
JP2024511373A (ja) | 2021-03-18 | 2024-03-13 | ノバルティス アーゲー | がんのためのバイオマーカーおよびその使用 |
JP2024514112A (ja) | 2021-04-06 | 2024-03-28 | ジェネンテック, インコーポレイテッド | ベルバラフェニブおよびコビメチニブを用いた併用療法、またはベルバラフェニブ、コビメチニブおよびアテゾリズマブを用いた併用療法 |
GB202107706D0 (en) | 2021-05-28 | 2021-07-14 | Adc Therapeutics S A | Combination therapy |
GB202107713D0 (en) | 2021-05-28 | 2021-07-14 | Medimmune Ltd | Combination therapy |
GB202107709D0 (en) | 2021-05-28 | 2021-07-14 | Adc Therapeutics S A | Combination therapy |
WO2022258612A1 (fr) | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | Polythérapie pour le traitement du cancer |
KR20240028449A (ko) | 2021-06-29 | 2024-03-05 | 에이디씨 테라퓨틱스 에스에이 | 항체-약물 접합체를 이용한 병용 요법 |
WO2023057545A1 (fr) | 2021-10-06 | 2023-04-13 | Microquin Ltd. | Chalcones substitués |
CN118201615A (zh) | 2021-11-04 | 2024-06-14 | 豪夫迈·罗氏有限公司 | 喹唑啉酮化合物用于治疗癌症的新用途 |
AU2022409717A1 (en) | 2021-12-16 | 2024-05-30 | Pags Co., Ltd. | Cell penetrating polypeptides (cpps) and their use in human therapy |
TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
US11780800B1 (en) | 2022-03-17 | 2023-10-10 | Springworks Therapeutics, Inc. | Fluorinated phenylamino compounds and pharmaceutical compositions |
EP4253418A1 (fr) | 2022-03-29 | 2023-10-04 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Cellules immunitaires exprimant des récepteurs d'antigène chimérique et anticorps bispécifiques et leurs utilisations |
GB202209285D0 (en) | 2022-06-24 | 2022-08-10 | Bergenbio Asa | Dosage regimen for AXL inhibitor |
WO2024033381A1 (fr) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition de tcf4/itf2 dans le traitement du cancer |
WO2024105144A1 (fr) | 2022-11-18 | 2024-05-23 | F. Hoffmann-La Roche Ag | Composé de quinazolinone en tant qu'inhibiteur de braf pour le traitement d'un cancer solide avancé ou de métastases |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4510139A (en) * | 1984-01-06 | 1985-04-09 | Sterling Drug Inc. | Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity |
US5155110A (en) | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
JPH03192592A (ja) | 1989-12-21 | 1991-08-22 | Matsushita Electric Ind Co Ltd | 磁気テープ記録再生装置 |
EP0754684A4 (fr) * | 1994-04-01 | 1998-05-13 | Shionogi & Co | Derive d'oxime et bactericide le contenant en tant qu'ingredient actif |
WO1997012613A1 (fr) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Procede de traitement et de prevention des inflammations et de l'atherosclerose |
US6251943B1 (en) | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
ES2229515T3 (es) | 1997-07-01 | 2005-04-16 | Warner-Lambert Company Llc | Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek. |
EP0993437B1 (fr) * | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | Derives d'acide benzoique 2-(4-bromo ou 4-iodo phenylamino) et utilisation de ces derniers en tant qu'inhibiteurs de mek |
US6974878B2 (en) * | 2001-03-21 | 2005-12-13 | Symyx Technologies, Inc. | Catalyst ligands, catalytic metal complexes and processes using same |
IL143231A0 (en) | 1998-12-15 | 2002-04-21 | Warner Lambert Co | Use of a mek inhibitors for preventing transplant rejection |
WO2000035436A2 (fr) | 1998-12-16 | 2000-06-22 | Warner-Lambert Company | Traitement de l'arthrite a l'aide d'inhibiteurs de la mek |
BR9916839A (pt) | 1998-12-22 | 2001-10-09 | Warner Lambert Co | Quimioterapia combinada |
KR20000047461A (ko) | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
JP2002534381A (ja) | 1999-01-07 | 2002-10-15 | ワーナー−ランバート・カンパニー | Mek阻害剤を用いた抗ウィルス法 |
WO2000040235A2 (fr) | 1999-01-07 | 2000-07-13 | Warner-Lambert Company | Traitement de l'asthme a l'aide d'inhibiteurs de mek |
HUP0105113A3 (en) * | 1999-01-13 | 2004-11-29 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds |
CA2349832A1 (fr) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Derives de benzenesulfonamide et leur utilisation comme inhibiteurs de mek |
NZ513432A (en) | 1999-01-13 | 2004-02-27 | Warner Lambert Co | 1-heterocycle substituted diarylamines |
CA2348236A1 (fr) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, et 4-arylthio diarylamines et leurs derives comme inhibiteurs selectifs de mek |
EP1150950A2 (fr) * | 1999-01-13 | 2001-11-07 | Warner-Lambert Company | Derives d'acide anthranilique |
PL352835A1 (en) | 1999-07-16 | 2003-09-08 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
AU5785900A (en) | 1999-07-16 | 2001-02-05 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
TR200200082T2 (tr) | 1999-07-16 | 2002-04-22 | Warner-Lambert Company | MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi. |
DK1202724T3 (da) | 1999-07-16 | 2004-01-26 | Warner Lambert Co | Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer |
EP1216228B1 (fr) | 1999-09-17 | 2008-10-29 | Millennium Pharmaceuticals, Inc. | BENZAMIDES ET INHIBITEURS CORRESPONDANTS DU FACTEUR Xa |
AU2001247372A1 (en) | 2000-03-15 | 2001-09-24 | Warner Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
CN1219753C (zh) | 2000-07-19 | 2005-09-21 | 沃尼尔·朗伯公司 | 4-碘苯氨基苯氧肟酸的氧合酯 |
IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
DE10141266A1 (de) * | 2001-08-21 | 2003-03-06 | Syntec Ges Fuer Chemie Und Tec | Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden |
JP2003192592A (ja) | 2001-10-17 | 2003-07-09 | Sankyo Co Ltd | 医薬組成物 |
JP2005507411A (ja) | 2001-10-31 | 2005-03-17 | ファイザー・プロダクツ・インク | 下肢静止不能症候群の治療における、ニコチン性アセチルコリン受容体アゴニスト。 |
DOP2003000556A (es) | 2002-01-23 | 2003-10-31 | Warner Lambert Co | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico. |
CA2473545A1 (fr) | 2002-01-23 | 2003-07-31 | Warner-Lambert Company Llc | Esters hydroxamates d'acide n-(phenyl substitue en 4)-anthranilique |
US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
UA76837C2 (uk) | 2002-03-13 | 2006-09-15 | Еррей Байофарма Інк. | N3 алкіловані похідні бензімідазолу як інгібітори мек |
ES2549159T3 (es) * | 2002-03-13 | 2015-10-23 | Array Biopharma, Inc. | Derivados de bencimidazol N3-alquilados como inhibidores de MEK |
WO2003103590A2 (fr) | 2002-06-11 | 2003-12-18 | Merck & Co., Inc. | Inhibiteurs de la kinase p38 (halo-benzo carbonyl)heterobicyclique |
GB0214268D0 (en) * | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
EP1606283B1 (fr) * | 2003-03-03 | 2008-10-08 | Array Biopharma, Inc. | Inhibiteurs de la p 38 et leurs procedes d'utilisation |
JP2005162727A (ja) | 2003-03-18 | 2005-06-23 | Sankyo Co Ltd | スルファミド誘導体及びその医薬組成物 |
TW200505834A (en) | 2003-03-18 | 2005-02-16 | Sankyo Co | Sulfamide derivative and the pharmaceutical composition thereof |
GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
EA010297B1 (ru) * | 2003-06-20 | 2008-08-29 | ЮСиБи ФАРМА С.А. | Производные тиенопиридона как ингибиторы киназ |
WO2005000818A1 (fr) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | Derives de 4-[phenylamino (substitue)]-2-pyridone a substitution en 5 en tant qu'inhibiteurs de la mek |
US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
WO2005007616A1 (fr) * | 2003-07-23 | 2005-01-27 | Warner-Lambert Company Llc | Derives de diphenylaminocetone utiles comme inhibiteurs de mek |
WO2005009975A2 (fr) * | 2003-07-24 | 2005-02-03 | Warner-Lambert Company Llc | Benzimidazoles n-methyle-substitues |
US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
JP4931419B2 (ja) * | 2003-09-19 | 2012-05-16 | 中外製薬株式会社 | 新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用 |
US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
DK1689233T3 (da) | 2003-11-19 | 2012-10-15 | Array Biopharma Inc | Bicykliske inhibitorer af MEK |
JP4527729B2 (ja) * | 2003-12-08 | 2010-08-18 | エフ.ホフマン−ラ ロシュ アーゲー | 新規チアゾール誘導体 |
MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
PE20060572A1 (es) | 2004-07-27 | 2006-06-27 | Novartis Ag | Compuestos de benzoimidazolona como inhibidores de hsp90 |
DK1802579T3 (da) * | 2004-10-20 | 2014-01-20 | Merck Serono Sa | Derivater af 3-arylaminopyridin |
WO2006061712A2 (fr) | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Utilisation d'inhibiteurs de mek dans le traitement d'une croissance cellulaire anormale |
US7547782B2 (en) * | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
EA025871B9 (ru) * | 2005-10-07 | 2017-08-31 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
EP2056829B9 (fr) * | 2006-08-16 | 2012-09-26 | Exelixis, Inc. | Procédés d'utilisation de modulateurs pi3k et mek |
-
2006
- 2006-10-05 EA EA201400111A patent/EA025871B9/ru not_active IP Right Cessation
- 2006-10-05 US US11/995,928 patent/US7803839B2/en active Active
- 2006-10-05 EP EP06825554A patent/EP1934174B1/fr active Active
- 2006-10-05 NO NO20200035A patent/NO347091B1/no unknown
- 2006-10-05 AT AT06825554T patent/ATE504565T1/de active
- 2006-10-05 CA CA2622755A patent/CA2622755C/fr active Active
- 2006-10-05 EA EA200801041A patent/EA019983B1/ru active Protection Beyond IP Right Term
- 2006-10-05 JP JP2008534706A patent/JP5129143B2/ja active Active
- 2006-10-05 CA CA3052368A patent/CA3052368A1/fr not_active Abandoned
- 2006-10-05 KR KR1020137010590A patent/KR20130058072A/ko not_active Application Discontinuation
- 2006-10-05 AU AU2006302415A patent/AU2006302415B2/en active Active
- 2006-10-05 SI SI200631043T patent/SI1934174T1/sl unknown
- 2006-10-05 WO PCT/US2006/039126 patent/WO2007044515A1/fr active Application Filing
- 2006-10-05 EA EA201691142A patent/EA032466B1/ru unknown
- 2006-10-05 GE GEAP200610685A patent/GEP20125456B/en unknown
- 2006-10-05 NZ NZ567140A patent/NZ567140A/en unknown
- 2006-10-05 CN CN201510197206.2A patent/CN104892582B/zh active Active
- 2006-10-05 ES ES06825554T patent/ES2365070T3/es active Active
- 2006-10-05 RS RS20110277A patent/RS51782B/en unknown
- 2006-10-05 CN CN201810489110.7A patent/CN109053523B/zh active Active
- 2006-10-05 PT PT06825554T patent/PT1934174E/pt unknown
- 2006-10-05 CN CN201310366896.0A patent/CN103524392B/zh active Active
- 2006-10-05 CA CA2927656A patent/CA2927656C/fr active Active
- 2006-10-05 MY MYPI20080982A patent/MY162174A/en unknown
- 2006-10-05 PL PL06825554T patent/PL1934174T3/pl unknown
- 2006-10-05 BR BRPI0617165A patent/BRPI0617165B1/pt active IP Right Grant
- 2006-10-05 CN CN2006800449476A patent/CN101365676B/zh active Active
- 2006-10-05 CN CN201910851634.0A patent/CN110668988A/zh active Pending
- 2006-10-05 DK DK06825554.6T patent/DK1934174T3/da active
- 2006-10-05 DE DE602006021205T patent/DE602006021205D1/de active Active
-
2008
- 2008-03-03 IL IL189900A patent/IL189900A/en active Protection Beyond IP Right Term
- 2008-03-05 ZA ZA200802075A patent/ZA200802075B/xx unknown
- 2008-04-04 KR KR1020087008141A patent/KR101341792B1/ko active Protection Beyond IP Right Term
- 2008-05-05 NO NO20082088A patent/NO344876B1/no active Protection Beyond IP Right Term
- 2008-11-25 HK HK08112886.4A patent/HK1119698A1/xx unknown
-
2010
- 2010-05-05 US US12/774,544 patent/US7915250B2/en active Active
-
2011
- 2011-03-15 US US13/048,832 patent/US8362002B2/en active Active
- 2011-07-04 CY CY20111100646T patent/CY1111670T1/el unknown
- 2011-07-05 HR HR20110498T patent/HRP20110498T1/hr unknown
-
2012
- 2012-09-05 JP JP2012195223A patent/JP5678019B2/ja active Active
-
2013
- 2013-06-27 US US13/929,062 patent/US20140275527A1/en not_active Abandoned
- 2013-10-30 IL IL229136A patent/IL229136A/en active IP Right Grant
-
2014
- 2014-03-13 JP JP2014049674A patent/JP5856211B2/ja active Active
- 2014-06-10 IL IL233053A patent/IL233053A0/en unknown
-
2015
- 2015-02-05 US US14/615,079 patent/US20170166523A9/en not_active Abandoned
- 2015-09-24 JP JP2015186392A patent/JP2015232045A/ja active Pending
-
2016
- 2016-03-07 HK HK16102537.8A patent/HK1214595A1/zh unknown
- 2016-05-13 HU HUS1600021C patent/HUS1600021I1/hu unknown
- 2016-05-17 LT LTPA2016016C patent/LTC1934174I2/lt unknown
- 2016-05-18 CY CY2016015C patent/CY2016015I1/el unknown
- 2016-05-18 NL NL300809C patent/NL300809I2/nl unknown
- 2016-05-19 FR FR16C0021C patent/FR16C0021I2/fr active Active
- 2016-05-19 LU LU93078C patent/LU93078I2/fr unknown
-
2017
- 2017-03-02 JP JP2017038954A patent/JP2017101071A/ja active Pending
- 2017-03-15 IL IL251185A patent/IL251185A0/en unknown
-
2018
- 2018-01-17 JP JP2018005721A patent/JP2018058907A/ja not_active Withdrawn
- 2018-04-13 US US15/952,923 patent/US20190144382A1/en not_active Abandoned
- 2018-06-19 IL IL260127A patent/IL260127B/en unknown
-
2019
- 2019-02-25 JP JP2019031850A patent/JP2019089841A/ja not_active Withdrawn
- 2019-10-09 US US16/597,607 patent/US20200031770A1/en not_active Abandoned
-
2020
- 2020-04-20 US US16/853,043 patent/US11597699B2/en active Active
- 2020-08-21 JP JP2020139894A patent/JP2020189882A/ja active Pending
- 2020-09-04 NO NO2020031C patent/NO2020031I1/no unknown
-
2023
- 2023-05-11 NO NO2023022C patent/NO2023022I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL260127B (en) | mek inhibitors and methods of using them | |
IN2014KN02886A (fr) | ||
TW200613243A (en) | Novel compounds | |
GEP20084439B (en) | Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof | |
MXPA06009475A (es) | Derivados de quinazolina y usos terapeuticos de los mismos. | |
TW200724537A (en) | Pyrimidine derivatives for treatment of hyperproliferative disorders | |
ATE493418T1 (de) | Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren | |
ATE532789T1 (de) | Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren | |
TW200639156A (en) | New compounds | |
EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
WO2008011539A3 (fr) | Composés anesthésiques | |
WO2003080624A3 (fr) | Nouveaux dithiolopyrrolones ayant une action therapeutique | |
UA96742C2 (en) | Mek inhibitors and use thereof | |
EA201990219A3 (ru) | Ингибиторы mek и способы их применения | |
UA95250C2 (ru) | Пиридинаминосульфонил-замещенные бензамиды как ингибиторы цитохром р450 3а4 (cyp4503a4) |